4D Molecular Therapeutics (FDMT) Accumulated Depreciation & Amortization (2019 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $18.8 million as the latest value for Q2 2025.
- On a quarterly basis, Accumulated Depreciation & Amortization changed N/A to $18.8 million in Q2 2025 year-over-year; TTM through Jun 2025 was $18.8 million, a N/A change, with the full-year FY2024 number at $16.6 million, up 39.0% from a year prior.
- Accumulated Depreciation & Amortization was $18.8 million for Q2 2025 at 4D Molecular Therapeutics, up from $16.6 million in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $18.8 million in Q2 2025 to a low of $4.2 million in Q1 2021.
- A 5-year average of $10.1 million and a median of $7.7 million in 2022 define the central range for Accumulated Depreciation & Amortization.
- Peak YoY movement for Accumulated Depreciation & Amortization: surged 35.09% in 2022, then skyrocketed 54.4% in 2023.
- 4D Molecular Therapeutics' Accumulated Depreciation & Amortization stood at $5.3 million in 2021, then surged by 45.13% to $7.7 million in 2022, then surged by 54.4% to $11.9 million in 2023, then surged by 39.0% to $16.6 million in 2024, then rose by 13.37% to $18.8 million in 2025.
- Per Business Quant, the three most recent readings for FDMT's Accumulated Depreciation & Amortization are $18.8 million (Q2 2025), $16.6 million (Q4 2024), and $15.5 million (Q3 2024).